Developing reversible safety switches for CAR-T cancer therapies
CAR-T cancer therapies can cause dangerous inflammation and neurological side effects when engineered immune cells become overactive. Conventional CAR-T cells are difficult to control after infusion, while suicide switches permanently eliminate the therapeutic cells.
Amatista Biotech is developing a reversible safety switch for CAR-T cancer therapies. It uses the drug erlotinib to temporarily pause engineered immune cells, aiming to help clinicians manage toxicity without destroying the therapeutic cells.
What stands out about Amatista Biotech
Company reports in vitro and in vivo studies showing CAR-T cell activity returns after withdrawal of the switch-control drug erlotinib.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.